63
Participants
Start Date
September 21, 2009
Primary Completion Date
October 20, 2015
Study Completion Date
October 20, 2015
catridecacog
Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
Novo Nordisk Investigational Site, Zurich
Novo Nordisk Investigational Site, Hershey
Novo Nordisk Investigational Site, Washington D.C.
Novo Nordisk Investigational Site, Richmond
Novo Nordisk Investigational Site, Valence
Novo Nordisk Investigational Site, Málaga
Novo Nordisk Investigational Site, Atlanta
Novo Nordisk Investigational Site, Tampa
Novo Nordisk Investigational Site, Vicenza
Novo Nordisk Investigational Site, Braunschweig
Novo Nordisk Investigational Site, Columbus
Novo Nordisk Investigational Site, Tortosa
Novo Nordisk Investigational Site, Duisburg
Novo Nordisk Investigational Site, Detroit
Novo Nordisk Investigational Site, Petah Tikva
Novo Nordisk Investigational Site, Bonn
Novo Nordisk Investigational Site, Minneapolis
Novo Nordisk Investigational Site, Oklahoma City
Novo Nordisk Investigational Site, Paris
Novo Nordisk Investigational Site, Rouen
Novo Nordisk Investigational Site, Boise
Novo Nordisk Investigational Site, Orange
Novo Nordisk Investigational Site, Le Kremlin-Bicêtre
Novo Nordisk Investigational Site, Seattle
Novo Nordisk Investigational Site, Klagenfurt
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Helsinki
Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima
Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Aberdeen
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Newcastle upon Tyne
Lead Sponsor
Novo Nordisk A/S
INDUSTRY